PHASE BEHAVIOR AND TRANSFORMATION KINETICS OF A POORLY WATER SOLUBLE WEAKLY BASIC DRUG UPON TRANSIT FROM LOW TO HIGH pH CONDITIONS <u>Tu V. Duong¹, David B. Turner², Lynne S. Taylor¹</u> ¹Purdue University, College of Pharmacy, West Lafayette, Indiana 47907, United States ²Certara UK Limited, Simcyp Division, Sheffield, S1 2BJ, United Kingdom

M1330-10-074


CONTACT INFORMATION: <u>vduong@purdue.edu</u>


PURPOSE

- Weakly basic compounds, which account for nearly 75% of marketed drugs, have an inherent tendency to undergo supersaturation in vivo upon transit from stomach to intestine.
- Phase behavior of a given compound can currently only be experimentally determined.
- We design *in vitro* experiments to define phase diagram of a model, poorly water soluble compound, posaconazole (PCZ), and evaluate its phase behavior and transformation kinetics.

METHODS

- Crystalline solubility: shake flask approach.
- Amorphous solubility: ultraviolet (UV) extinction method.
- Induction time: monitor the concentration and turbidity of a solution as a function of time using an in situ UV probe.








Figure 3. Modified pH-solubility phase diagram of PCZ.

phosphate buffer and FaSSIF V1.

ADVANCING PHARMACEUTICAL SCIENCES, CAREERS, AND COMMUNITY

CONCLUSIONS

- Solubility of posaconazole as a function of pH follows the Henderson-Hasselbalch equation.
- pH-solubility phase diagram is constructed to define possible phase transformations, namely crystallization or liquid-liquid phase separation.
- Nucleation induction time varies as a function of degree of supersaturation.
- Nucleation mechanism can change from homogeneous at high supersaturation to heterogeneous at low supersaturation.
- Medium composition significantly affects phase boundaries and nucleation induction time.
- Findings for posaconazole could be broadly applicable to other weakly basic compounds, after taking into consideration differences in pK_a, solubility and molecular structure.

FUNDING

The authors would like to acknowledge the financial support from U.S. Food and Drug Administration via a GDUFA regulatory research contract (HHSF223201710137C).

